(FIGURE 1) Primary efficacy endpoint of NOV03 in SEECASE trial. (All figures courtesy of Novaliq)

(FIGURE 2) Symptom improvement of NOV03 in SEECASE trial. (All figures courtesy of Novaliq)

(FIGURE 3) Primary efficacy endpoint of CyclASol 0.1% in ESSENCE trial. (All figures courtesy of Novaliq)